溶剂挥发法制备牛樟芝总三萜微囊的研究
|
摘要
目的制备包载牛樟芝总三萜的微囊。方法以微囊的表征形态及粒径分布为检测指标,对微囊制备过程中的挥发温度、溶剂体积、相体积比例、搅拌速率及抗粘剂五个影响因素进行单因素考察,以初步优化牛樟芝总三萜微囊制备工艺。结果溶剂挥发法制备包载牛樟芝总三萜的微囊工艺为:牛樟芝总三萜用量0.10g,聚丙烯酸树脂Ⅱ号用量0.60g,混合溶剂体积(甲醇/丙酮=1∶5,v/v)12.0mL,液体石蜡体积120.0mL,司班80(乳化剂)用量0.80g,硬脂酸铝(抗粘剂)用量0.060g,挥发温度35℃,乳化时间20min,搅拌速率570r·min~(-1)。结论溶剂挥发法制备包载牛樟芝总三萜微囊的制备工艺切实可行。
OBJECTIVE To prepare microcapsules loaded Antrodia cinnamomea total triterpene.METHODS With the outside morphology and particle size distribution of microcapsules as the test indexes,the volatilization temperature,volume of solvent,phase volume ratio,stirring rate and anti viscosity agent in the preparation of microcapsules were investigated to optimize the preparation technology of Antrodia cinnamomea total triterpene microcapsules.RESULTS The best microencapsulation process of the Antrodia cinnamomea total triterpene carried by the solvent volatilization method,according to the single factor investigation,was:Antrodia cinnamomea alcohol extract 0.10 g,polyacrylic acid resin Ⅱ0.60 g,mixed solvent(methanol/acetone=1∶5,v/v) 12.0 mL,liquid paraffin120.0 mL,span80,emulsifier dosage of 0.80 g,aluminum stearate(an adhesive) 0.060 g,stir and emulsify at 10℃ for 20 minutes,and then heat up to 35℃,keep stirring for 1.5 hours,the stirring speed was kept in 570 r·min~(-1).CONCLUSION The preparation of Antrodia cinnamomea total triterpene microcapsules by the solvent evaporation method is feasible.
OBJECTIVE To prepare microcapsules loaded Antrodia cinnamomea total triterpene.METHODS With the outside morphology and particle size distribution of microcapsules as the test indexes,the volatilization temperature,volume of solvent,phase volume ratio,stirring rate and anti viscosity agent in the preparation of microcapsules were investigated to optimize the preparation technology of Antrodia cinnamomea total triterpene microcapsules.RESULTS The best microencapsulation process of the Antrodia cinnamomea total triterpene carried by the solvent volatilization method,according to the single factor investigation,was:Antrodia cinnamomea alcohol extract 0.10 g,polyacrylic acid resin Ⅱ0.60 g,mixed solvent(methanol/acetone=1∶5,v/v) 12.0 mL,liquid paraffin120.0 mL,span80,emulsifier dosage of 0.80 g,aluminum stearate(an adhesive) 0.060 g,stir and emulsify at 10℃ for 20 minutes,and then heat up to 35℃,keep stirring for 1.5 hours,the stirring speed was kept in 570 r·min~(-1).CONCLUSION The preparation of Antrodia cinnamomea total triterpene microcapsules by the solvent evaporation method is feasible.
引文
[1]张知晓,季梅,泽桑梓.牛樟芝培养技术的研究进展[J].热带农业科学,2015,35(3):94-99.
[2]张远腾,李晓波.牛樟芝化学成分及其药理作用研究进展[J].中草药,2016,47(6):1034-1042.
[3]Geethangili MT,Zeng YM.Reviewof pharmacological effects of Ant-rodia camphmata and its bioactive compounds[J].Evidence-Based Complemen-tary andAlternative Medicine,2009,51(9):1-15.
[4]赖敏男.台湾牛樟芝发展史及人工栽培现况[J].食药用菌,2017,30(2):84-89.
[5]Cherng I,Chiang H,Wu D.Triterpenoids from Antrodia cinnamomea[J].Phytochemistry,1996,41(5):263-267.
[6]Chiou JF,Wu A TH,Wang WT,et al.A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging[J].Evidence-Based Complementray and Alternative Medicine,2011,46(1):914561.
[7]徐小伟,泽桑梓,杨斌,等.牛樟芝主要活性成分及其药理研究现状[J].林业调查规划,2014,39(6):21-25.
[8]张毅红,赵宗杰,谢海涛,等.樟芝三萜类化合物的抗炎作用[J].中国病理生理杂志,2015,31(2):369-373 .
[9]贺元川,陈仕江,贺宗毅,等.樟芝三萜研究进展[J].重庆中草药研究,2012,38(2):19-25.
[10]赵春艳,吴素蕊,高观世,等.牛樟芝药用功能成分作用及应用进展[J].食品工业科技,2016,37(23):391-395.
[11]苏志诚.台湾牛樟芝的性味、归经与功效的探讨「J]中医临床研究,2013,5(20):26,30.
[12]王丽平,陆小路,赵宗杰.中药牛樟芝研究进展[J].今日药学,2017,27(2):140-144.
[13]李腾霞.微囊的制备及研究进展[J].广州医药,2010,41(6):18-20.
[14]董志俭.复合凝聚薄荷油微胶囊的研究[D].无锡:江南大学,2008.
[15]袁帅.载药微囊的制备与表征实验研究[D].合肥:中国科学技术大学,2017.
[16]Shaoping Sun,Na Liang,Hiromitsu Yamamoto,et al.pH-sensitive poly(lactide-co-glycolide)nanoparticle com-posite microcapsules for oral delivery of insulin[J].Inter-national Journal of Nanomedicine,2015,136(10):3489-3498.
[17]Ford Versypt AN,Pack DW,Braatz RD.Mathematical modeling of drug delivery from autocatalytically degrad-able PLGA mierospheres-a review[J].J Control Release,2013,165(1):29-37.
[18]马桂芝,滕亮,李文英,等.乳化-溶剂挥发法制备左旋多巴微囊[J].新疆医科大学学报,2014,37(1):47-50.
[19]陈进,何争民.微囊的研究和应用进展[J].安徽医药,2010,14(12):1484-1486.
[20]陈虹舟,马仕昆,胡龙驹,等.骨碎补总黄酮/聚乳酸-羟基乙酸微囊的制备[J].中国组织工程研究,2015,19(52):8473-8479.
[21]孙万峰,初志敏.液中干燥法制备阿莫西林微囊的研究.中国药学杂志,2002,37(25):352-354.
[22]张宇,黄洪,陈阳青.头孢克肟微囊制备工艺研究[J].中国处方药,2017,15(11):22-23.
[23]张少孩,王鸿,尚小广.马钱子碱微囊制备工艺的研究[J].中国现代医生,2017,55(27):42-45.
[24]汪丽芬.盐酸小檗碱肠溶微囊的制备及体外评价[D].武汉:华中科技大学,2007.
[25]符华林,叶连娟,张伟,等.地克珠利肠溶微囊的制备及其特性的研究[J].中国兽医科学,2011,41(3):308,313.
[26]罗丽娟,胡延春,舒刚,等.枸橼酸铁肠溶微囊的制备及评价[J].中国医药工业杂志,2015,46(1):40-43.
[27]王建筑,郝吉福,李菲,等.乳化-溶剂挥发法制备阿司匹林乙基纤维素微囊[J].西北药学杂志,2013,28 (2):188-191.
[28]王光磊,洪华炜,王宫.几种提取技术在樟芝总三萜提取中的应用和比较[J].海峡药学,2014,26(8):31-33.
[29]夏慧亭.复凝聚法制备橄榄油微胶囊及其性质研究[D].哈尔滨:东北农业大学,2016.
[30]岳红坤,周冉,王景翔,等.黄芩苷缓释微囊的制备方法及稳定性的研究[J].井冈山大学学报:自然科学版,2013,34(6):88-92.
[31]田燕,蒋妮,田舸,等.齐墩果酸微囊的制备及质量考察[J].大连医科大学学报,2007,86(02):118-119,129.
[32]孙芸,刘艺,燕雪花,等.甘草黄酮微囊的制备及其理化性质的研究[J].新疆医科大学学报,2011,34(03):270-273.
[33]王昭.芍药苷微囊的测定及制备研究[J].亚太传统医药,2014,10(17):41-42.
[34]董自亮,卢君蓉,高飞,等.芍药苷微囊的制备及其体外释药研究[J].中草药,2013,44(13):1756-1760.
[35]陆仕华,刘华钢,赖玲,等.三七总皂苷肠溶微囊的制备及体外释放度[J].中国实验方剂学杂志,2011,64(14):11-14.
[36]王家远,杨波,赵榆林,等.壳聚糖-三七总皂苷缓释微囊的制备及体外溶出研究[J].中国药业,2006,69(17):28-29.[36]Mundargi RC,Babu VR,Rangaswamy V,et al.Nano/microtechnologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives[J].J Control Release,2008,125(3):193-209.
[2]张远腾,李晓波.牛樟芝化学成分及其药理作用研究进展[J].中草药,2016,47(6):1034-1042.
[3]Geethangili MT,Zeng YM.Reviewof pharmacological effects of Ant-rodia camphmata and its bioactive compounds[J].Evidence-Based Complemen-tary andAlternative Medicine,2009,51(9):1-15.
[4]赖敏男.台湾牛樟芝发展史及人工栽培现况[J].食药用菌,2017,30(2):84-89.
[5]Cherng I,Chiang H,Wu D.Triterpenoids from Antrodia cinnamomea[J].Phytochemistry,1996,41(5):263-267.
[6]Chiou JF,Wu A TH,Wang WT,et al.A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging[J].Evidence-Based Complementray and Alternative Medicine,2011,46(1):914561.
[7]徐小伟,泽桑梓,杨斌,等.牛樟芝主要活性成分及其药理研究现状[J].林业调查规划,2014,39(6):21-25.
[8]张毅红,赵宗杰,谢海涛,等.樟芝三萜类化合物的抗炎作用[J].中国病理生理杂志,2015,31(2):369-373 .
[9]贺元川,陈仕江,贺宗毅,等.樟芝三萜研究进展[J].重庆中草药研究,2012,38(2):19-25.
[10]赵春艳,吴素蕊,高观世,等.牛樟芝药用功能成分作用及应用进展[J].食品工业科技,2016,37(23):391-395.
[11]苏志诚.台湾牛樟芝的性味、归经与功效的探讨「J]中医临床研究,2013,5(20):26,30.
[12]王丽平,陆小路,赵宗杰.中药牛樟芝研究进展[J].今日药学,2017,27(2):140-144.
[13]李腾霞.微囊的制备及研究进展[J].广州医药,2010,41(6):18-20.
[14]董志俭.复合凝聚薄荷油微胶囊的研究[D].无锡:江南大学,2008.
[15]袁帅.载药微囊的制备与表征实验研究[D].合肥:中国科学技术大学,2017.
[16]Shaoping Sun,Na Liang,Hiromitsu Yamamoto,et al.pH-sensitive poly(lactide-co-glycolide)nanoparticle com-posite microcapsules for oral delivery of insulin[J].Inter-national Journal of Nanomedicine,2015,136(10):3489-3498.
[17]Ford Versypt AN,Pack DW,Braatz RD.Mathematical modeling of drug delivery from autocatalytically degrad-able PLGA mierospheres-a review[J].J Control Release,2013,165(1):29-37.
[18]马桂芝,滕亮,李文英,等.乳化-溶剂挥发法制备左旋多巴微囊[J].新疆医科大学学报,2014,37(1):47-50.
[19]陈进,何争民.微囊的研究和应用进展[J].安徽医药,2010,14(12):1484-1486.
[20]陈虹舟,马仕昆,胡龙驹,等.骨碎补总黄酮/聚乳酸-羟基乙酸微囊的制备[J].中国组织工程研究,2015,19(52):8473-8479.
[21]孙万峰,初志敏.液中干燥法制备阿莫西林微囊的研究.中国药学杂志,2002,37(25):352-354.
[22]张宇,黄洪,陈阳青.头孢克肟微囊制备工艺研究[J].中国处方药,2017,15(11):22-23.
[23]张少孩,王鸿,尚小广.马钱子碱微囊制备工艺的研究[J].中国现代医生,2017,55(27):42-45.
[24]汪丽芬.盐酸小檗碱肠溶微囊的制备及体外评价[D].武汉:华中科技大学,2007.
[25]符华林,叶连娟,张伟,等.地克珠利肠溶微囊的制备及其特性的研究[J].中国兽医科学,2011,41(3):308,313.
[26]罗丽娟,胡延春,舒刚,等.枸橼酸铁肠溶微囊的制备及评价[J].中国医药工业杂志,2015,46(1):40-43.
[27]王建筑,郝吉福,李菲,等.乳化-溶剂挥发法制备阿司匹林乙基纤维素微囊[J].西北药学杂志,2013,28 (2):188-191.
[28]王光磊,洪华炜,王宫.几种提取技术在樟芝总三萜提取中的应用和比较[J].海峡药学,2014,26(8):31-33.
[29]夏慧亭.复凝聚法制备橄榄油微胶囊及其性质研究[D].哈尔滨:东北农业大学,2016.
[30]岳红坤,周冉,王景翔,等.黄芩苷缓释微囊的制备方法及稳定性的研究[J].井冈山大学学报:自然科学版,2013,34(6):88-92.
[31]田燕,蒋妮,田舸,等.齐墩果酸微囊的制备及质量考察[J].大连医科大学学报,2007,86(02):118-119,129.
[32]孙芸,刘艺,燕雪花,等.甘草黄酮微囊的制备及其理化性质的研究[J].新疆医科大学学报,2011,34(03):270-273.
[33]王昭.芍药苷微囊的测定及制备研究[J].亚太传统医药,2014,10(17):41-42.
[34]董自亮,卢君蓉,高飞,等.芍药苷微囊的制备及其体外释药研究[J].中草药,2013,44(13):1756-1760.
[35]陆仕华,刘华钢,赖玲,等.三七总皂苷肠溶微囊的制备及体外释放度[J].中国实验方剂学杂志,2011,64(14):11-14.
[36]王家远,杨波,赵榆林,等.壳聚糖-三七总皂苷缓释微囊的制备及体外溶出研究[J].中国药业,2006,69(17):28-29.[36]Mundargi RC,Babu VR,Rangaswamy V,et al.Nano/microtechnologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives[J].J Control Release,2008,125(3):193-209.